CA2898550C - Oxazolidone compound, preparing method and application thereof - Google Patents

Oxazolidone compound, preparing method and application thereof Download PDF

Info

Publication number
CA2898550C
CA2898550C CA2898550A CA2898550A CA2898550C CA 2898550 C CA2898550 C CA 2898550C CA 2898550 A CA2898550 A CA 2898550A CA 2898550 A CA2898550 A CA 2898550A CA 2898550 C CA2898550 C CA 2898550C
Authority
CA
Canada
Prior art keywords
compound
substituted
heterocyclic group
room temperature
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2898550A
Other languages
English (en)
French (fr)
Other versions
CA2898550A1 (en
Inventor
Yushe Yang
Tao Xue
Shi DING
Bin Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
ZHE JIANG JUTAI PHARMACEUTICAL Co Ltd
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZHE JIANG JUTAI PHARMACEUTICAL Co Ltd, Shanghai Institute of Materia Medica of CAS filed Critical ZHE JIANG JUTAI PHARMACEUTICAL Co Ltd
Publication of CA2898550A1 publication Critical patent/CA2898550A1/en
Application granted granted Critical
Publication of CA2898550C publication Critical patent/CA2898550C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA2898550A 2013-01-18 2013-12-30 Oxazolidone compound, preparing method and application thereof Active CA2898550C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310020040.8A CN103936763B (zh) 2013-01-18 2013-01-18 噁唑烷酮类化合物及其制备方法和用途
CN201310020040.8 2013-01-18
PCT/CN2013/090833 WO2014110971A1 (zh) 2013-01-18 2013-12-30 噁唑烷酮类化合物及其制备方法和用途

Publications (2)

Publication Number Publication Date
CA2898550A1 CA2898550A1 (en) 2014-07-24
CA2898550C true CA2898550C (en) 2016-08-02

Family

ID=51184670

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2898550A Active CA2898550C (en) 2013-01-18 2013-12-30 Oxazolidone compound, preparing method and application thereof

Country Status (8)

Country Link
US (1) US9382265B2 (https=)
EP (1) EP2947085B1 (https=)
JP (1) JP6242915B2 (https=)
KR (1) KR101756570B1 (https=)
CN (1) CN103936763B (https=)
AU (1) AU2013373885B2 (https=)
CA (1) CA2898550C (https=)
WO (1) WO2014110971A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105593232B (zh) * 2013-09-29 2018-06-26 华北制药集团新药研究开发有限责任公司 作为凝血因子Xa抑制剂的苯并恶唑并恶嗪酮类化合物
WO2015110024A1 (en) * 2014-01-24 2015-07-30 Sunshine Lake Pharma Co., Ltd. Oxazolidinone compounds and their uses in pharmaceuticals
WO2015176677A1 (en) * 2014-05-22 2015-11-26 Sunshine Lake Pharma Co., Ltd. Crystalline forms and amorphism of oxazolidinone compound
CN105693746B (zh) * 2014-06-14 2018-09-14 广东东阳光药业有限公司 噁唑烷酮类化合物的制备方法及其中间体
CN105503903B (zh) * 2014-09-26 2019-04-26 华北制药集团新药研究开发有限责任公司 苯并恶唑并恶嗪酮类化合物的制备方法及其中间体和晶型
CN104672236B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含双酰胺基和卤代苯结构的FXa抑制剂及其用途
CN104610260B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途
CN104610258B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含酰胺和甲氧苯结构的FXa抑制剂、制备方法及其用途
CN106478658A (zh) * 2015-08-25 2017-03-08 华北制药集团新药研究开发有限责任公司 苯并恶唑并恶嗪酮类化合物wa1-089的晶型d及其制备方法
CN106478661A (zh) * 2015-08-25 2017-03-08 华北制药集团新药研究开发有限责任公司 苯并恶唑并恶嗪酮类化合物wa1-089的晶型e及其制备方法
CN105348275A (zh) * 2015-12-10 2016-02-24 中国药科大学 噁唑烷酮类化合物及其合成方法与医药应用
CN108069983A (zh) * 2016-11-10 2018-05-25 浙江普洛得邦制药有限公司 一种噁唑烷酮类化合物的晶型及其制备方法和应用
CN108395442A (zh) * 2017-02-07 2018-08-14 浙江普洛得邦制药有限公司 一种噁唑烷酮类化合物的晶型vii及其制备方法和应用
CN108727406B (zh) 2017-03-28 2021-12-07 北京协和制药二厂 含氮杂环取代的苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
CN109111465B (zh) * 2017-06-22 2021-01-12 中国科学院上海药物研究所 噻唑烷酮螺嘧啶三酮类化合物及制备方法和用途
CN108912142B (zh) * 2018-08-08 2021-06-18 延边大学 吡咯并苯并恶嗪酮类化合物及其注射剂和在抗血栓中的用途
CN114685529A (zh) * 2020-12-29 2022-07-01 中国科学院上海药物研究所 噁唑烷酮类化合物的无定形物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19805117A1 (de) * 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
TWI396686B (zh) * 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
JPWO2010071164A1 (ja) * 2008-12-19 2012-05-31 第一三共株式会社 活性化血液凝固第Ｘ因子（ＦＸａ）阻害剤
CN102260277B (zh) * 2010-05-24 2013-07-24 中国科学院上海药物研究所 新型苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
CN102464658B (zh) * 2010-11-03 2014-04-16 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途

Also Published As

Publication number Publication date
CN103936763B (zh) 2017-10-31
JP6242915B2 (ja) 2017-12-06
WO2014110971A1 (zh) 2014-07-24
EP2947085A1 (en) 2015-11-25
AU2013373885B2 (en) 2016-07-14
KR101756570B1 (ko) 2017-07-10
US20150361091A1 (en) 2015-12-17
JP2016513076A (ja) 2016-05-12
CN103936763A (zh) 2014-07-23
EP2947085B1 (en) 2017-09-13
EP2947085A4 (en) 2016-06-22
US9382265B2 (en) 2016-07-05
KR20150105466A (ko) 2015-09-16
AU2013373885A1 (en) 2015-08-27
CA2898550A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
CA2898550C (en) Oxazolidone compound, preparing method and application thereof
AU2020207089B2 (en) 15-PGDH inhibitor
JP6957516B2 (ja) カリクレインインヒビターとしての、ｎ−［（３−フルオロ−４−メトキシピリジン−２−イル）メチル］−３−（メトキシメチル）−１−（｛４−［（２−オキソピリジン−１−イル）メチル］フェニル｝メチル）ピラゾール−４−カルボキサミドの多形体
KR102494647B1 (ko) 비시클릭 헤테로아릴 치환된 화합물
CA3128062A1 (en) Benzopyridone heterocyclic compound and use thereof
JP2022501354A (ja) ピルビン酸キナーゼｒの活性化
JP2021504317A (ja) ハロアリルアミン類のｓｓａｏ／ｖａｐ−１阻害剤とその用途
WO2002047679A2 (en) Nonpeptide agonists and antagonists of vasopressin receptors
KR102492715B1 (ko) 모노시클릭 헤테로아릴 치환된 화합물
WO2016001631A1 (en) Benzoxazinone amides as mineralocorticoid receptor modulators
KR101083506B1 (ko) 신규한 헤테로아릴 융합된 환형 아민
KR20190026906A (ko) Par4 억제제로서의 트리시클릭 헤테로아릴-치환된 퀴놀린 및 아자퀴놀린 화합물
JP2009515925A (ja) 凝固第Ｘａ因子のインヒビターとしての新規なピロリジン誘導体
CN105218564A (zh) 三环噁唑烷酮类化合物及其制备方法和用途
CN120077042A (zh) 作为因子XIIa抑制剂的3A,4,5,6-四氢-1H-吡唑并[3,4-C]吡啶-7(7AH)-酮衍生物
CN113527261B (zh) 吡啶酮或嘧啶酮类衍生物及其制备方法和用途
CN111303146A (zh) 3-氰基吡啶类化合物、包含其的药物组合物及其制备方法和用途
CN110759901A (zh) 四氢异喹啉类衍生物及其制备方法和用途
TW202412765A (zh) 酶抑制劑
CN116829547A (zh) 因子XIIa抑制剂
JPS5912663B2 (ja) Ｎ↑ｇ−置換−Ｎ↑２−ナフタレンスルホニルアルギニンアミド類またはその酸付加塩の製造法
EA046481B1 (ru) Ингибитор 15-pgdh

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150717

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251003

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226